Gyre Therapeutics
GYRE
46 hedge funds and large institutions have $72.8M invested in Gyre Therapeutics in 2015 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 7 closing their positions.
822% more call options, than puts
Call options by funds: $83K | Put options by funds: $9K
3% less capital invested
Capital invested by funds: $75.1M → $72.8M (-$2.31M)
6% less funds holding
Funds holding: 49 → 46 (-3)
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| 1 |
DCM
DG Capital Management
New York
|
+$4.08M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$309K |
| 3 |
Renaissance Technologies
New York
|
+$196K |
| 4 |
AA
Ancora Advisors
Cleveland,
Ohio
|
+$126K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$126K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TDC
51
Thompson Davis & Co
Richmond,
Virginia
| – | -$42K | -18 | Closed |
|
52
Citadel Advisors
Miami,
Florida
| – | -$41K | -17 | Closed |
|
53
Invesco
Atlanta,
Georgia
| – | -$10K | -4 | Closed |
|
|
AIG
54
American International Group
New York
| – | -$1.49K | -1 | Closed |
|
55
Creative Planning
Overland Park,
Kansas
| – | -$1K | – | – |
|
GYRE Hedge Fund Activity: Q2 2015 in Review
46 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q2 2015, worth a combined $72.8M — down 3.1% from $75.1M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of GYRE and 4 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 8 added.
The largest buyer was DG Capital Management, opening a new position worth an estimated $4.08M. The largest seller was Vanguard Group, cutting an estimated $1.24M.
- 46 institutional investors held Gyre Therapeutics (GYRE) as of Q2 2015, down from 49 in Q1 2015.
- Funds reported $72.8M of Gyre Therapeutics stock for Q2 2015, down 3.1% quarter-over-quarter.
- 4 funds opened new Gyre Therapeutics positions in Q2 2015 and 7 closed out, a net change of -3 holders.
- The largest Gyre Therapeutics buyer in Q2 2015 was DG Capital Management, an estimated $4.08M added.
- The largest Gyre Therapeutics seller in Q2 2015 was Vanguard Group, an estimated $1.24M sold.
Based on aggregated 13F filings for Q2 2015.